V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10004607 | 10002907 | null | null | Curative (C) | null | 2017-12-29 | Palbociclib | N | N | 10537601 | CARBOPLATIN + RT |
| 10004608 | 10002908 | 1.72 | 97.3 | Palliative (P) | 2013-07-07 | 2013-07-07 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 02 | N | 10537685 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 10004609 | 10002909 | 1.7 | null | Curative (C) | 2013-11-13 | 2013-11-13 | R Chlorambucil | 02 | null | 10537747 | CETUXIMAB + RT |
| 10004610 | 10002910 | 1.69 | 58 | Palliative (P) | 2018-01-05 | 2018-01-05 | AC | 02 | null | 10537906 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 10004611 | 10002911 | 1.63 | 72.5 | Disease modification (D) | 2015-07-09 | 2015-07-15 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | N | N | 10537922 | AC |
| 10004612 | 10002912 | 1.65 | 84 | Curative (C) | 2017-03-20 | 2017-03-23 | Sorafenib | null | null | 10538200 | BEVACIZUMAB |
| 10004613 | 10002913 | 1.75 | 73 | Palliative (P) | 2015-12-14 | 2015-12-22 | LENALIDOMIDE | N | N | 10538248 | CISPLATIN + FLUOROURACIL + RT |
| 10004614 | 10002913 | 1.69 | null | Palliative (P) | 2017-03-23 | 2017-03-28 | Vinorelbine (oral) | N | N | 10538248 | CISPLATIN + FLUOROURACIL |
| 10004615 | 10002914 | 1.6 | null | Disease modification (D) | 2014-12-02 | 2014-12-14 | CLADRIBINE | N | N | 10538482 | CARBOPLATIN + DOCETAXEL |
| 10004616 | 10002915 | 1.84 | 62.7 | Palliative (P) | 2018-12-12 | 2018-12-12 | Mitomycin Intravesical | 2 | null | 10538505 | IPILIMUMAB + NIVOLUMAB |
| 10004617 | 10002915 | 1.74 | null | Palliative (P) | 2017-11-18 | 2017-11-18 | Pazopanib | N | N | 10538505 | CAPECITABINE + CARBOPLATIN |
| 10004618 | 10002916 | 1.61 | 77.5 | Palliative (P) | 2016-09-01 | 2016-09-24 | GEFITINIB | 02 | Y | 10538600 | PERTUZUMAB |
| 10004619 | 10002917 | 1.86 | 74.9 | null | 2017-09-25 | 2017-09-26 | Mitomycin Intravesical | 2 | N | 10538612 | DA |
| 10004620 | 10002918 | null | 75.8 | Not known (9) | 2017-03-05 | 2017-03-05 | EP | N | N | 10538673 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 10004621 | 10002919 | 1.6 | 65.5 | Neo-adjuvant (N) | 2016-08-19 | 2016-08-26 | Ipilimumab | N | Y | 10538752 | LENALIDOMIDE |
| 10004622 | 10006679 | 0 | 88.8 | Not known (9) | 2014-11-23 | 2014-12-21 | FLUOROURACIL + MITOMYCIN | N | N | 10538791 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 10004623 | 10002920 | 1.78 | 75.6 | Curative (C) | 2018-03-03 | 2018-03-26 | FLAIR Trial | 02 | N | 10538801 | FLUOROURACIL + MITOMYCIN |
| 10004624 | 10002921 | 1.53 | null | Palliative (P) | 2017-07-30 | 2017-07-30 | Cetuximab 14 day | null | null | 10538869 | TEMOZOLOMIDE |
| 10004625 | 10002922 | 1.72 | 72.3 | Neo-adjuvant (N) | 2014-12-03 | 2014-12-11 | CAPECITABINE + IRINOTECAN | 2 | N | 10539022 | CETUXIMAB + IRINOTECAN + MDG |
| 10004626 | 10002923 | null | 75.1 | Curative (C) | 2016-11-28 | 2016-12-14 | THALIDOMIDE | N | N | 10539026 | MITOMYCIN INTRAVESICULAR |
| 10004627 | 10002924 | null | 68.4 | Palliative (P) | 2014-08-18 | 2014-08-24 | TRASTUZUMAB | 2 | N | 10539033 | AFATINIB |
| 10004628 | 10002924 | 0 | 100.9 | Disease modification (D) | 2017-10-31 | 2017-11-10 | Arsenic Triox + Tretinoin Ind W1-4 | N | N | 10539033 | BORTEZOMIB + THALIDOMIDE |
| 10004629 | 10002925 | 1.75 | 70.5 | Palliative (P) | 2018-01-17 | 2018-02-02 | FCR | 2 | N | 10539214 | CLADRIBINE |
| 10004630 | 10002925 | 1.63 | 90 | Palliative (P) | 2018-08-26 | 2018-08-28 | AML 19 TRIAL | 2 | null | 10539214 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10004631 | 10002925 | null | 76.85 | null | 2018-03-11 | 2018-03-18 | BORTEZOMIB + THALIDOMIDE | 02 | null | 10539214 | MPV |
| 10004632 | 10002925 | 1.81 | 75.6 | Palliative (P) | 2017-01-27 | 2017-01-27 | DABRAFENIB + TRAMETINIB | N | N | 10539214 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10004633 | 10002926 | null | null | null | 2014-08-05 | 2014-08-05 | Cyclophosphamide + Docetaxel | 02 | N | 10539530 | CISPLATIN + FLUOROURACIL |
| 10004634 | 10002927 | 1.74 | 40 | Palliative (P) | 2017-09-17 | 2017-09-24 | CETUXIMAB + IRINOTECAN + MDG | 2 | N | 10539671 | TEMOZOLOMIDE |
| 10004635 | 10002928 | 1.61 | null | Curative (C) | null | 2017-11-18 | DA | 02 | N | 10539685 | MITOMYCIN INTRAVESICULAR |
| 10004636 | 10002929 | null | 56.5 | Adjuvant (A) | null | 2019-05-28 | Cyclophosphamide + Dex + Rituximab | N | N | 10539701 | CHLVPP |
| 10004637 | 10002930 | 0 | 0 | Disease modification (D) | 2016-10-06 | 2016-10-15 | Cytarabine Low Dose | N | N | 10539712 | STAMPEDE TRIAL |
| 10004638 | 10002931 | 1.77 | 79 | Disease modification (D) | 2017-06-22 | 2017-06-23 | LENALIDOMIDE | N | N | 10539770 | MPV |
| 10004639 | 10002931 | 1.75 | 64.2 | Palliative (P) | 2015-06-01 | 2015-06-01 | Cape+Cisplatin+Trastuzumab Load | null | null | 10539770 | MPV |
| 10004640 | 10002932 | 1.72 | 81.2 | Adjuvant (A) | 2016-08-23 | 2016-09-06 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | 10540024 | BEP |
| 10004641 | 10002933 | null | 70 | Curative (C) | 2018-11-22 | 2018-12-12 | BORTEZOMIB + THALIDOMIDE | N | N | 10540104 | CRIZOTINIB |
| 10004642 | 10002934 | 1.76 | 110.3 | Adjuvant (A) | 2018-08-24 | 2018-08-26 | Sorafenib | 02 | N | 10540235 | MITOMYCIN |
| 10004643 | 10002934 | 1.8 | 0 | Neo-adjuvant (N) | 2016-01-25 | 2016-01-27 | DA | 2 | N | 10540235 | CYCLOPHOSPHAMIDE |
| 10004644 | 10002935 | 1.71 | 69.4 | Curative (C) | 2018-10-16 | 2018-10-16 | CARFILZOMIB | N | N | 10540257 | AFATINIB |
| 10004645 | 10002935 | 1.71 | 68 | Disease modification (D) | 2017-01-03 | 2017-01-09 | CHOP R + METHOTREXATE | 02 | N | 10540257 | LENALIDOMIDE |
| 10004646 | 10008204 | 1.57 | 63.5 | Palliative (P) | 2016-10-01 | 2016-10-14 | CHLORAMBUCIL + RITUXIMAB | 02 | null | 10540456 | FEC + DOCETAXEL + TRASTUZUMAB |
| 10004647 | 10008848 | 1.66 | 79.79 | Adjuvant (A) | 2015-09-11 | 2015-09-25 | CARBOPLATIN + RT | 02 | null | 10540584 | ERLOTINIB |
| 10004648 | 10008848 | 1.86 | 97 | Palliative (P) | 2016-10-03 | 2016-10-04 | Sunitinib | 02 | null | 10540584 | CAPECITABINE + MITOMYCIN + RT |
| 10004649 | 10008848 | 1.7 | null | Curative (C) | 2016-10-23 | 2016-10-30 | Doxorubicin + Olaratumab | null | N | 10540584 | MELPHALAN |
| 10004650 | 10008848 | 1.7 | 70.2 | Neo-adjuvant (N) | 2016-09-17 | 2016-09-17 | Cisplatin + Docetaxel | N | N | 10540584 | CISPLATIN + ETOPOSIDE + RT |
| 10004651 | 10002936 | 0 | 47.1 | Neo-adjuvant (N) | 2016-03-30 | 2016-04-19 | Bortezomib + MELPHALAN | N | N | 10540840 | VINBLASTINE |
| 10004652 | 10002937 | 1.63 | 0 | Palliative (P) | 2017-11-09 | 2017-11-18 | MIC | 02 | Y | 10540927 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10004653 | 10002938 | 1.68 | 84 | Palliative (P) | 2017-04-10 | 2017-04-11 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 10540976 | IPILIMUMAB + NIVOLUMAB |
| 10004654 | 10002939 | 1.77 | 0 | Palliative (P) | 2015-07-24 | 2015-07-29 | Ixazomib + Lenalidomide | N | N | 10541003 | CARBOPLATIN + DOCETAXEL |
| 10004655 | 10002940 | null | 64.1 | Disease modification (D) | 2016-11-18 | 2016-11-18 | Alemtuzumab | N | N | 10541015 | SUNITINIB |
| 10004656 | 10002940 | 1.78 | 63 | Palliative (P) | 2018-09-20 | 2018-10-20 | IPILIMUMAB + NIVOLUMAB | 01 | Y | 10541015 | FLUOROURACIL + MITOMYCIN |